On April 28, 2026, Boehringer Ingelheim and Zealand Pharma reported topline Phase 3 results for survodutide, their once-weekly GLP-1/glucagon dual receptor agonist. SYNCHRONIZE-1 hit its co-primary endpoints: 16.6% mean body weight loss at 76 weeks, with up to 85.1% of participants achieving at least 5% weight loss. It is the first dual glucagon/GLP-1 agonist to deliver a Phase 3 obesity readout — and the number lands almost exactly between semaglutide and tirzepatide.
Research-context information only. Survodutide is an investigational drug not approved by the FDA. Phase 3 data discussed below come from press disclosures by Boehringer Ingelheim and Zealand Pharma. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what was published — not what should be done. Consult a licensed physician for personal medical decisions.
What SYNCHRONIZE-1 Showed
SYNCHRONIZE-1 enrolled 725 adults with obesity (BMI greater than or equal to 30) or overweight with at least one weight-related complication, and excluded participants with type 2 diabetes. Patients were randomized to weekly subcutaneous survodutide at 3.6 mg or 6.0 mg, or to matched placebo, for 76 weeks of treatment.
| Endpoint | Survodutide | Placebo |
|---|---|---|
| Mean body weight loss (efficacy estimand) | 16.6% | 3.2% |
| Approximate pounds lost | ~39.2 lb (17.8 kg) | ~7-8 lb |
| Achieved greater than or equal to 5% weight loss | 85.1% | 38.8% |
| Waist circumference reduction | Statistically significant vs placebo | — |
Boehringer reported the topline as a pooled or "up to" figure across the 3.6 mg and 6.0 mg arms; full dose-by-dose breakdowns will be presented at the American Diabetes Association Scientific Sessions in June 2026, along with the LIVERAGE and LIVERAGE-Cirrhosis MASH readouts later in 2026.
Two body-composition signals matter beyond the headline percentage:
- Fat-driven weight loss. Initial analysis indicates the weight reduction was driven predominantly by fat mass, with lean mass contributing only a small proportion. This matches the mechanistic argument for adding glucagon receptor agonism — increased energy expenditure and hepatic fat oxidation tend to spare lean tissue compared with caloric restriction alone.
- Waist circumference. A statistically significant decrease vs placebo, a marker tied to visceral fat and cardiometabolic risk.
Sources: Boehringer Ingelheim release | Zealand Pharma announcement | PharmaTimes coverage | BioPharma Dive analysis.
Where Survodutide Lands Against the Class
The 16.6% number is the right starting point for comparison shopping. It is meaningful — placebo-adjusted weight loss above 13 points is clinically significant — but it does not reorder the obesity drug hierarchy:
| Drug | Mechanism | Highest-dose Phase 3 weight loss | Trial / source |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | ~15-17% at 68 weeks | STEP 1 (Wilding et al., NEJM 2021) |
| Survodutide 3.6-6.0 mg | GLP-1 + glucagon | 16.6% at 76 weeks | SYNCHRONIZE-1 (April 2026) |
| Tirzepatide 15 mg | GIP + GLP-1 | ~22.5% at 72 weeks | SURMOUNT-1 (Jastreboff et al., NEJM 2022) |
| Retatrutide 12 mg | GIP + GLP-1 + glucagon | 28.7% at 68 weeks | TRIUMPH-4 (phase 3 results) |
That puts survodutide effectively tied with semaglutide and clearly below tirzepatide and retatrutide for raw weight loss. Where survodutide may distinguish itself is in liver disease — the 83% MASH resolution rate from Phase 2 was the standout signal for the molecule, and the LIVERAGE Phase 3 readouts later in 2026 will determine whether survodutide carves out a MASH/MASLD niche the GIP-containing drugs cannot.
Wall Street analysts at BioPharma Dive characterized the 16.6% as "comparable to Wegovy but short of what's been seen in testing of Zepbound" — meaning survodutide is unlikely to lead on weight loss alone. Its commercial path likely runs through liver disease and any cardiovascular outcomes data the SYNCHRONIZE Cardiovascular Outcomes Trial eventually produces.
What This Means If You Are Buying Now
Survodutide is not FDA approved. Boehringer has not announced an FDA filing date. Most analysts assume submission in late 2027 with a possible decision window through 2028 — best case, two and a half years from today before any pharmacy can dispense it. Until then, survodutide exists only in two channels:
- Active clinical trials. Boehringer is enrolling SYNCHRONIZE-2, the cardiovascular outcomes study, and the LIVERAGE program. Eligible patients can find sites at clinicaltrials.gov.
- Research peptide vendors. Several gray-market vendors stock survodutide as research-grade material. Quality varies. The Phase 3 data validates the mechanism but says nothing about what is actually in a vial sold online — third-party COA testing matters more for survodutide than for established compounds because the 39-amino-acid synthesis is harder than BPC-157 or sermorelin.
If you are sourcing survodutide for research, focus on vendors that publish recent third-party (Janoshik or Anresco) HPLC and mass spec results for survodutide specifically — not just generic vendor-wide certificates. Compare the in-stock options at /peptides/survodutide and the live coupon stack at /deals/.
Compare Top Peptides
Best vendor pricing, COA verified, with active discount codes
